Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients

被引:3
|
作者
Tsou, Yi-Fan [1 ]
Lin, Niang-Cheng [1 ]
Hsia, Cheng-Yuan [1 ,2 ]
Loong, Che-Chuan [1 ,2 ]
Tsai, Hsin-Lin [1 ,3 ]
Chen, Cheng-Yen [1 ]
Lei, Hao-Jan [1 ,2 ]
Chou, Shu-Cheng [1 ,2 ]
Chung, Meng-Hsuan [1 ]
Kuo, Fang-Cheng [1 ]
Liu, Chin-Su [1 ,3 ]
机构
[1] Taipei Vet Gen Hosp, Dept Surg, Div Transplantat Surg, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Surg, Div Pediat Surg, Taipei, Taiwan
关键词
Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Loco-regional therapy; Outcomes; CHEMOEMBOLIZATION; IMPACT;
D O I
10.1097/JCMA.0000000000000670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver transplantation is the definitive treatment for defined stage hepatocellular carcinoma (HCC) in cirrhotic patients. Loco-regional therapy (LRT) may be considered before transplantation to prevent the disease progression and the patient from dropping out of the waiting list. This study aims to evaluate the impact of repeated pretransplant LRTs on the long-term outcomes in HCC liver transplant recipients. Methods: Between 2004 and 2019, living donor liver transplantation (LDLT) recipients with viable HCC on the explant livers were enrolled. Uni- and multivariate analysis was performed with the Cox regression model to stratify the risk factors associated with HCC recurrence and patent survival after LDLT. Results: A total of 124 patients were enrolled, in which 65.3% (n = 81) were Barcelona Clinic Liver Cancer classification stage B or D and 89% (n = 110) had advanced fibrosis or cirrhosis on the explanted livers. After a median follow-up of 41 months (IQR: 24-86.5), there were 18 cases (13.7%) of HCC recurrence. Univariate analysis showed that the model of end-stage liver disease and Child-Turcotte-Pugh score, pretransplant alpha-fetoprotein value (>500 ng/ml), repeated pretransplant LRTs (N > 4), increased tumor numbers and maximal size, presence of microvascular invasion, and the histological grading of the tumors are risk factors of inferior outcomes. In multivariate analysis, only repeated pretransplant LRTs (N > 4) had a significant impact on both the overall- and recurrence-free survival. The impact of pretransplant LRT was consistently significant among subgroups based on their LRT episodes (N = 0, 1-4, >4 respectively). Conclusion: Repeated LRT for HCC can be associated with the risk of tumor recurrence and inferior patient survival after LDLT in cirrhotic patients. Early referral of those eligible for transplantation may improve the treatment outcomes in these patients.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [31] Outcome of Living Donor Liver Transplantation for Patients with Far Advanced Hepatocellular Carcinoma.
    Suh, Kyung-Suk
    Hong, Geun
    Kim, Hyeyoung
    Park, Min-Su
    Choi, Young-Rok
    Mori, Shozo
    Shin, Woo Young
    Lee, H. W.
    Yi, Nam-Joon
    Lee, Kwang-Woong
    LIVER TRANSPLANTATION, 2012, 18 : S214 - S214
  • [32] Inferior Vena Cava Replacement in Living Donor Liver Transplantation for Hepatocellular Carcinoma
    Chen, Chao-Long
    Concejero, Allan M.
    Wang, Chih-Chi
    Wang, Shih-Ho
    Liu, Yueh-Wei
    Yang, Chin-Hsiang
    Yong, Chee-Chien
    Lin, Tsan-Shiun
    LIVER TRANSPLANTATION, 2009, 15 (11) : 1637 - 1640
  • [33] OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION FOR INCIDENTALLY FOUND HEPATOCELLULAR CARCINOMA
    Said, Mohamed
    Yosry, Ayman
    Esmat, Gamal
    El-Serafy, Magdy
    Omar, Ashraf
    Doss, Waheed
    Hosny, Adel
    Hatata, Yaser
    Marawan, Ebrahem
    Kamel, Refat Refat
    El-Taweel, Ahmad
    Dosoky, Ayman
    Ghaly, Ahmad
    El-Gabaly, Hatem
    TRANSPLANT INTERNATIONAL, 2009, 22 : 198 - 198
  • [34] Outcome of hepatocellular carcinoma treated by liver transplantation: comparison of living donor and deceased donor transplantation
    Li, Chuan
    Wen, Tian-Fu
    Yan, Lu-Nan
    Li, Bo
    Yang, Jia-Ying
    Wang, Wen-Tao
    Xu, Ming-Qing
    Wei, Yong-Gang
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2010, 9 (04) : 366 - 369
  • [36] An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma
    Bimonte, Sabrina
    Barbieri, Antonio
    Palaia, Raffaele
    Leongito, Maddalena
    Albino, Vittorio
    Piccirillo, Mauro
    Arra, Claudio
    Izzo, Francesco
    INFECTIOUS AGENTS AND CANCER, 2015, 10
  • [37] An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma
    Sabrina Bimonte
    Antonio Barbieri
    Raffaele Palaia
    Maddalena Leongito
    Vittorio Albino
    Mauro Piccirillo
    Claudio Arra
    Francesco Izzo
    Infectious Agents and Cancer, 10
  • [38] Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma
    Antwi, Samuel O.
    Habboush, Yacob Y.
    Chase, Lori A.
    Lee, David D.
    Patel, Tushar
    ANNALS OF HEPATOLOGY, 2018, 17 (06) : 969 - 979
  • [39] Indications for living donor liver transplantation in patients with hepatocellular carcinoma
    Sugawara, Yasuhiko
    Inomata, Yukihiro
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (05) : 429 - 432
  • [40] LIVING DONOR LIVER TRANSPLANTATION FOR PATIENTS WITH RECURRENT HEPATOCELLULAR CARCINOMA
    Takada, Yasutsugu
    Ueda, Mikiko
    Egawa, Hiroto
    Uemoto, Shinji
    LIVER TRANSPLANTATION, 2008, 14 (07) : S121 - S122